Black Diamond Therapeutics Inc

+0.04 (+1.93%)
4:08:28 PM EDT: $2.04 -0.07 (-3.32%)
Earnings Announcements

Black Diamond Therapeutics Reports Quarterly Loss Of $0.60 Per Share

Published: 11/08/2022 13:07 GMT
Black Diamond Therapeutics Inc (BDTX) - Black Diamond Therapeutics- Cash, Cash Equivalents & Investments of $144.2 Million at Quarter End Expected to Be Sufficient to Fund Operations Into Q3 2024.
Qtrly Loss per Share $0.60.
Q3 Earnings per Share View $-0.64 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.63

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.57

More details on our Analysts Page.